# Five Peptides, Five Positions on the Translational Gap

> Compare the Five Peptides — Avant Peptides — A side-by-side comparison of semaglutide, tirzepatide, tesamorelin, BPC-157, and PT-141 across mechanism, regulatory status, and evidence maturity — the translational gap, laid out at a glance.

**COMPARE**

Same organizing question across every row: what does each peptide do, what is it approved for, and how far has the human evidence actually gone?

## The short version

Reading five peptide profiles side by side is more useful than reading them one at a time, because the differences between them are exactly the point. Two of these compounds — semaglutide and tirzepatide — are backed by tens of thousands of trial participants and multiple regulatory approvals. Two more — tesamorelin and PT-141 — are approved, but each for one narrow, specific population. One, BPC-157, has not reached human-trial approval at all.

The table below lines up mechanism, regulatory status, and evidence maturity for all five. Read it as a map of where each compound sits on the translational gap, not a ranking of which is "best" — a peptide with a narrow approval isn't a lesser compound, it's a compound that has only been rigorously tested for one thing.

## Mechanism and target

| Peptide | Receptor / target | What it engages |
|---|---|---|
| [Semaglutide](/semaglutide) | GLP-1 receptor | One incretin hormone receptor; appetite and glucose regulation |
| [Tirzepatide](/tirzepatide) | GIP + GLP-1 receptors | Two incretin hormone receptors at once ("dual agonist") |
| [Tesamorelin](/tesamorelin) | GHRH receptor | Pituitary signal that triggers the body's own growth-hormone release |
| [BPC-157](/bpc-157) | VEGFR2 (angiogenesis) + others | Blood-vessel-growth signaling tied to tissue repair |
| [PT-141](/pt-141) | MC4R (melanocortin) | Central brain circuits governing sexual desire |

Each compound engages a different biological system, which is part of why they don't compete with each other for the same use — they're grouped here for what they illustrate about the research process, not because they treat the same condition.

## Regulatory status and approved use

| Peptide | FDA status | Approved for |
|---|---|---|
| Semaglutide | Approved (multiple indications) | Type 2 diabetes, chronic weight management, cardiovascular risk reduction, MASH |
| Tirzepatide | Approved (multiple indications) | Type 2 diabetes, chronic weight management, obstructive sleep apnea |
| Tesamorelin | Approved (single indication) | Excess visceral fat in HIV-associated lipodystrophy only |
| PT-141 | Approved (single indication, single population) | Acquired, generalized HSDD in premenopausal women only |
| BPC-157 | Not approved | No approved human indication; research use only |

The gap between "approved" and "approved for the use under discussion" is a common source of confusion in public conversations. Tesamorelin and PT-141 are FDA-approved medicines, but for populations and conditions much narrower than the broader conversation around them often implies [13][24][26].

## Evidence maturity

| Peptide | Human evidence base | Trial scale |
|---|---|---|
| Semaglutide | Extensive; multiple outcome trials | Tens of thousands of participants across trials [1][2][3][4][7] |
| Tirzepatide | Extensive; multiple outcome and head-to-head trials | Thousands of participants across trials [1][9][10][11] |
| Tesamorelin | Established within its indication | Hundreds of participants across a focused trial program [12][14][16] |
| PT-141 | Established within its indication | Over 1,200 participants across pivotal Phase 3 trials [24][25] |
| BPC-157 | Minimal | As of the most recent review, only three small human pilot studies [17][18] |

This is the row that most directly answers the translational-gap question. Semaglutide and tirzepatide sit at one extreme, with dense, multi-indication trial programs. BPC-157 sits at the other, with a rodent literature that is genuinely large but a human literature that is genuinely small. Tesamorelin and PT-141 occupy the useful middle ground: solid, focused trial programs that support a real approval, without the breadth of the incretin-class evidence base.

## Reading these five together

None of these compounds compete for the same clinical use, so this is not a head-to-head comparison in the way [semaglutide and tirzepatide compare](/tirzepatide) to each other. It is a comparison of five points on the same underlying question: how does a molecule get from a laboratory finding to something a regulator has reviewed and approved, and what does the distance traveled say about the weight a claim can carry?

A claim backed by a 17,604-person cardiovascular outcomes trial [3] and a claim backed by a two-person safety pilot [17] can both be true and accurately reported — but they carry very different amounts of evidentiary weight. A careful reader treats them differently. That is the habit this site is built to encourage. For the source list behind every figure on this page, see [references](/references).

---

Avant Peptides independently maps the distance from peptide benchwork to approved medicine; it is an editorial digest, not a clinic, pharmacy, or prescription.